Angus brings over 25 years of R&D and Business Development experience to DDF.
Angus joined DDF in July 2018 as CEO.
DDF Portfolio Board Roles
Alchemab Therapeutics, Caraway Therapeutics, Cerevance, and Tiaki Therapeutics
Prior to joining the DDF, Angus worked at Celgene for 12 years. He started at Celgene as Vice President North American Regulatory Affairs in 2006, in the Summit NJ Headquarters. In 2008, Angus moved to London as Head of Europe RA for three years to build out the function and support the integration of Pharmion. Angus returned to the Summit NJ Headquarters as VP, Business Development and Global Alliances in 2011 where he built and grew the alliance management function to manage over 60 collaborations while completing multiple innovative deals. In 2016, Angus focused on deals, serving as Corporate VP of Business Development, leading a BD team running the transactions from deal inception to close as well as select acquisitions, before leaving Celgene for the DDF. Angus previously worked at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the US FDA, Center for Biologics. Angus currently serves at the Chairman of the Board for Toronto Innovation and Acceleration Partners.
Angus received his undergraduate degree from the University of Richmond, then his Ph.D. in Anatomy & Immunology from the Medical College of Virginia and completed his post-doctoral training at the National Cancer Institute in Bethesda.